二十年后的结直肠癌预后。
Colorectal cancer prognosis twenty years later.
机构信息
Departament of Gastroenterology, CIBEREHD, University of Country Basque, Donostia Hospital, Avda. Sancho El Sabio, 17-2D, 20010 San Sebastián, Spain.
出版信息
World J Gastroenterol. 2010 Feb 21;16(7):862-7. doi: 10.3748/wjg.v16.i7.862.
Abstract
AIM
To evaluate changes in colorectal cancer (CRC) survival over the last 20 years.
METHODS
We compared two groups of consecutive CRC patients that were prospectively recruited: Group I included 1990 patients diagnosed between 1980 and 1994. Group II included 871 patients diagnosed in 2001.
RESULTS
The average follow up time was 21 mo (1-229) for Group I and 50 mo (1-73.4) for Group II. Overall median survival was significantly longer in Group II than in Group I (73 mo vs 25 mo, P < 0.001) and the difference was significant for all tumor stages. Post surgical mortality was 8% for Group Iand 2% for Group II (P < 0.001). Only 17% of GroupI patients received chemotherapy compared with 50% of Group II patients (P < 0.001).
CONCLUSION
Survival in colorectal cancer patients has doubled over the past 20 years. This increase seems to be partly due to the generalization in the administration of chemotherapy and to the decrease of post surgical mortality.
摘要
目的
评估过去 20 年来结直肠癌（CRC）生存情况的变化。
方法
我们比较了两组连续的 CRC 患者，这些患者是前瞻性招募的：第 I 组包括 1990 名 1980 年至 1994 年期间诊断为 CRC 的患者。第 II 组包括 871 名 2001 年诊断为 CRC 的患者。
结果
第 I 组的平均随访时间为 21 个月（1-229），第 II 组为 50 个月（1-73.4）。第 II 组的总体中位生存时间明显长于第 I 组（73 个月比 25 个月，P <0.001），所有肿瘤分期的差异均有统计学意义。第 I 组术后死亡率为 8%，第 II 组为 2%（P <0.001）。第 I 组仅有 17%的患者接受化疗，而第 II 组有 50%的患者接受化疗（P <0.001）。
结论
在过去的 20 年中，结直肠癌患者的生存率提高了一倍。这种增加似乎部分归因于化疗的广泛应用和术后死亡率的降低。
相似文献
1
Colorectal cancer prognosis twenty years later.二十年后的结直肠癌预后。
World J Gastroenterol. 2010 Feb 21;16(7):862-7. doi: 10.3748/wjg.v16.i7.862.
2
Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.老年II/III期结直肠癌患者的低剂量卡培他滨辅助化疗（LC-ACEC）：一项随机对照试验的研究方案
Trials. 2015 May 29;16:238. doi: 10.1186/s13063-015-0753-7.
3
Is perineural invasion (PN) a determinant of disease free survival in early stage colorectal cancer?神经周围浸润（PN）是早期结直肠癌无病生存期的决定因素吗？
Hepatogastroenterology. 2015 Jan-Feb;62(137):59-64.
4
Clinical characteristics and treatment propensity in elderly patients aged over 80 years with colorectal cancer.80 岁以上老年结直肠癌患者的临床特征和治疗倾向。
Korean J Intern Med. 2018 Nov;33(6):1182-1193. doi: 10.3904/kjim.2016.181. Epub 2017 Nov 24.
5
Does resection of primary lesions show survival benefit for stage IV colorectal cancer patients with unresectable metastases?对于伴有不可切除转移灶的IV期结直肠癌患者，切除原发灶是否能带来生存获益？
Hepatogastroenterology. 2013 Nov-Dec;60(128):1945-9.
6
Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.基于组合癌症特征的基因签名集的鉴定和构建，以预测 II 期结直肠癌的复发和化疗获益。
JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413.
7
Long-term outcomes after surgical resection in patients with stage IV colorectal cancer: a retrospective study of 129 patients at a single institution.单中心 129 例患者的回顾性研究：外科切除治疗 IV 期结直肠癌的长期疗效。
World J Surg Oncol. 2019 Mar 23;17(1):56. doi: 10.1186/s12957-019-1599-3.
8
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.转移性结直肠癌患者生存率的提高与肝切除的采用及化疗的改善有关。
J Clin Oncol. 2009 Aug 1;27(22):3677-83. doi: 10.1200/JCO.2008.20.5278. Epub 2009 May 26.
9
Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients.十年间结肠癌和直肠癌的手术结果：来自902例未经选择患者的连续单中心经验结果。
World J Surg Oncol. 2007 Jul 4;5:73. doi: 10.1186/1477-7819-5-73.
10
Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.辅助化疗可提高IIA期结肠癌患者的生存率并降低复发率。
Hepatogastroenterology. 2012 Nov-Dec;59(120):2466-71. doi: 10.5754/hge10260.
引用本文的文献
1
Dose Reduction and Diagnostic Performance of Tin Filter-Based Spectral Shaping CT in Patients with Colorectal Cancer.基于锡滤器的光谱成形 CT 在结直肠癌患者中的剂量降低与诊断性能。
Tomography. 2022 Apr 8;8(2):1079-1089. doi: 10.3390/tomography8020088.
2
Is CT-based body composition associated with long-term chemotherapy-induced peripheral neuropathy in colorectal cancer survivors?基于CT的身体成分与结直肠癌幸存者长期化疗引起的周围神经病变有关吗？
Support Care Cancer. 2022 Jul;30(7):6071-6078. doi: 10.1007/s00520-022-07036-z. Epub 2022 Apr 13.
3
Colorectal cancer survival rates in Makassar, Eastern Indonesia: A retrospective Cohort Study.印度尼西亚东部望加锡的结直肠癌生存率：一项回顾性队列研究。
Ann Med Surg (Lond). 2021 Dec 30;74:103211. doi: 10.1016/j.amsu.2021.103211. eCollection 2022 Feb.
4
Colorectal Cancer Prevalence and Survival in Cuenca (Spain).西班牙昆卡地区结直肠癌的流行率与存活率
J Gastrointest Cancer. 2023 Mar;54(1):80-89. doi: 10.1007/s12029-021-00784-x. Epub 2022 Jan 13.
5
The Effectiveness of Glutathione Redox Status as a Possible Tumor Marker in Colorectal Cancer.谷胱甘肽氧化还原状态作为结直肠癌肿瘤标志物的有效性。
Int J Mol Sci. 2021 Jun 8;22(12):6183. doi: 10.3390/ijms22126183.
6
The effect of radiotherapy on rectal cancer: a histopathological appraisal and prognostic indicators.放疗对直肠癌的影响：组织病理学评估及预后指标
Radiat Oncol J. 2020 Jun;38(2):77-83. doi: 10.3857/roj.2020.00010. Epub 2020 Jun 16.
7
Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.解释结直肠癌对药物治疗耐药性的细胞机制。
Cancers (Basel). 2020 Sep 11;12(9):2605. doi: 10.3390/cancers12092605.
8
Cell Death by Gallotannin Is Associated with Inhibition of the JAK/STAT Pathway in Human Colon Cancer Cells.没食子单宁诱导的细胞死亡与人类结肠癌细胞中JAK/STAT信号通路的抑制相关。
Curr Ther Res Clin Exp. 2020 Jun 13;92:100589. doi: 10.1016/j.curtheres.2020.100589. eCollection 2020.
9
High-throughput screening reveals higher synergistic effect of MEK inhibitor combinations in colon cancer spheroids.高通量筛选揭示 MEK 抑制剂联合在结肠癌球体中具有更高的协同效应。
Sci Rep. 2020 Jul 14;10(1):11574. doi: 10.1038/s41598-020-68441-0.
10
Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.结直肠癌幸存者中疼痛性和非疼痛性化疗诱导性周围神经病与生活质量：基于人群的 PROFILES 登记处的结果。
Support Care Cancer. 2020 Dec;28(12):5933-5941. doi: 10.1007/s00520-020-05438-5. Epub 2020 Apr 12.
本文引用的文献
1
Colorectal cancer surgery in the elderly: acceptable morbidity?老年患者的结直肠癌手术：可接受的发病率？
Am J Surg. 2008 Mar;195(3):344-8; discussion 348. doi: 10.1016/j.amjsurg.2007.12.022.
2
Causes of high mortality in colorectal surgery: a review of episodes of care in Veterans Affairs hospitals.结直肠手术高死亡率的原因：对退伍军人事务部医院护理事件的回顾
Am J Surg. 2007 Nov;194(5):639-45. doi: 10.1016/j.amjsurg.2007.08.004.
3
Comparison of colonic stenting and open surgery for malignant large bowel obstruction.结肠癌性肠梗阻结肠支架置入术与开放手术的比较
Surg Endosc. 2007 Feb;21(2):225-33. doi: 10.1007/s00464-005-0644-1. Epub 2006 Dec 9.
4
Clinical performance of original and revised Bethesda guidelines for the identification of MSH2/MLH1 gene carriers in patients with newly diagnosed colorectal cancer: proposal of a new and simpler set of recommendations.用于识别新诊断结直肠癌患者中MSH2/MLH1基因携带者的原始及修订版贝塞斯达指南的临床性能：一套新的更简化建议方案
Am J Gastroenterol. 2006 May;101(5):1104-11. doi: 10.1111/j.1572-0241.2006.00522.x.
5
Thirty-day mortality after surgery for colorectal cancer in Denmark.丹麦结直肠癌手术后的30天死亡率。
Colorectal Dis. 2005 Sep;7(5):500-6. doi: 10.1111/j.1463-1318.2005.00793.x.
6
Adjuvant therapy for colon cancer--the pace quickens.结肠癌辅助治疗——步伐加快。
N Engl J Med. 2005 Jun 30;352(26):2746-8. doi: 10.1056/NEJMe058117.
7
Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.修订的贝塞斯达指南、微卫星不稳定性及免疫组织化学在遗传性非息肉病性结直肠癌患者识别中的准确性
JAMA. 2005 Apr 27;293(16):1986-94. doi: 10.1001/jama.293.16.1986.
8
Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study.法国接受结直肠手术患者的术后死亡率和发病率：一项前瞻性多中心研究的结果
Arch Surg. 2005 Mar;140(3):278-83, discussion 284. doi: 10.1001/archsurg.140.3.278.
9
Thirty-day mortality from colorectal cancer surgery within a deprived population.贫困人群中结直肠癌手术的30天死亡率。
Colorectal Dis. 2005 Mar;7(2):193-5. doi: 10.1111/j.1463-1318.2004.00742.x.
10
Morbidity and mortality of colorectal carcinoma surgery differs by insurance status.结直肠癌手术的发病率和死亡率因保险状况而异。
Cancer. 2004 Nov 15;101(10):2187-94. doi: 10.1002/cncr.20624.
Zotero 插件